[Hereditary breast cancer: treatment and prevention].
In general, the treatment of early breast cancer is guided by the results from large randomised trials. The same does not apply to patients who carry BRCA1/2 mutations. The selection of loco-regional therapies might change according to BRCA1/2 mutation status. In order to reduce the risk of secondary breast and ovarian cancer, these patients may also be offered prophylactic oophorectomy. The possible impact of BRCA1/2 mutations on the efficacy of medical therapies has recently attained much interest, alongside the development of targeted therapies against BRCA1/2 associated cancers.
Ejlertsen
Bent
B
Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø. bent.ejlertsen@rh.hosp.dk
Gerdes
Anne-Marie A
AM
D001943:Breast Neoplasms / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005820:Genetic Testing; D006801:Humans; D008408:Mastectomy; D009154:Mutation; D010051:Ovarian Neoplasms / Q000517:prevention & control; D010052:Ovariectomy; D011379:Prognosis; D012307:Risk Factors